Matthew Vander Heiden
马修·范德海登
MD, PhD
Associate Director, Koch Institute for Integrative Cancer Research科赫综合癌症研究所副所长
👥Biography 个人简介
Matthew Vander Heiden is a leading authority on cancer metabolism, elucidating how tumors rewire metabolic pathways to support proliferation. His research has illuminated IDH mutations, the Warburg effect, and metabolic vulnerabilities that can be exploited therapeutically.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PKM2 and the Warburg Effect
Demonstrated that cancer cells express PKM2 to support biosynthesis over ATP production, providing mechanistic insight into the Warburg effect and metabolic reprogramming in tumors.
IDH Mutant Cancer Metabolism
Characterized metabolic consequences of IDH1/2 mutations and 2-hydroxyglutarate production in glioma and AML, supporting the clinical development of IDH inhibitors enasidenib and ivosidenib.
Representative Works 代表性著作
Understanding the Warburg Effect: the metabolic requirements of cell proliferation
Science (2009)
Landmark review reframing the Warburg effect as a metabolic adaptation supporting biosynthesis in proliferating cells, reshaping the field of cancer metabolism.
Pyruvate kinase M2 is a phosphotyrosine-binding protein
Nature (2008)
Revealed growth factor signaling inhibits PKM2 to redirect glucose carbons into biosynthesis, explaining how oncogenic signaling coordinates metabolic reprogramming.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Sebastian Bauer
University Hospital Essen (Universitätsklinikum Essen)
Suzanne George
Dana-Farber Cancer Institute / Harvard Medical School
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
关注 马修·范德海登 的研究动态
Follow Matthew Vander Heiden's research updates
留下邮箱，当我们发布与 Matthew Vander Heiden（Massachusetts Institute of Technology）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment